secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001493152-24-039392
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.04, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem receives $106.8M debt acceleration notice; closes $460K private placement with Aditxt
--------------------------------------------------------------------------------

- Future Pak LLC (agent) claims Event of Default under SPA; repurchase price ~$106.8M if all Purchasers exercise Section 5.7 Option.
- Evofem 'strongly disagrees' with default claim and intends to vigorously contest it.
- Closed private placement with Aditxt: 460 shares Series F-1 Preferred for $460,000; registration rights granted.
- Third Amendment to Merger Agreement adjusts Aditxt equity investment: 720 shares due Oct 2, 2280 shares due Oct 31.
- Merger sub (Adifem) to merge into Evofem; Evofem to become wholly owned subsidiary of Aditxt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224039392/0001493152-24-039392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224039392/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer